HIGH EXPOSURE TO INFLIXIMAB IS ASSOCIATED WITH INCREASED RISK OF INFECTIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

被引：0
|
作者：
Landemaine, Amandine
Petitcollin, Antoine
Miard, Celine
Brochard, Charlene
Dewitte, Marie
Laurent, Siproudhis
Bouguen, Guillaume
机构：
来源：
GASTROENTEROLOGY | 2019年 / 156卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Su1836
引用
收藏
页码：S628 / S629
页数：2
相关论文
共 50 条
  • [1] FRAILITY IS ASSOCIATED WITH AN INCREASED RISK OF INFECTIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS ON IMMUNOSUPPRESSION
    Kochar, Bharati
    Cai, Winston
    Cagan, Andrew
    Ananthakrishnan, Ashwin
    [J]. GASTROENTEROLOGY, 2020, 158 (06) : S54 - S54
  • [2] Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease
    Hyams, Jeffrey S.
    Dubinsky, Marla C.
    Baldassano, Robert N.
    Colletti, Richard B.
    Cucchiara, Salvatore
    Escher, Johanna
    Faubion, William
    Fell, John
    Gold, Benjamin D.
    Griffiths, Anne
    Koletzko, Sibylle
    Kugathasan, Subra
    Markowitz, James
    Ruemmele, Frank M.
    Veereman, Gigi
    Winter, Harland
    Masel, Nicholas
    Shin, Chu Ri
    Tang, Kezhen L.
    Thayu, Meena
    [J]. GASTROENTEROLOGY, 2017, 152 (08) : 1901 - +
  • [3] Infliximab use in patients with inflammatory bowel disease and the risk of serious bacterial infections
    Schneeweiss, Sebastian
    Solomon, Daniel
    Korzenik, Joshua
    Canning, Claire
    Bressler, Brian
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 : S62 - S62
  • [4] Infliximab use in patients with inflammatory bowel disease and the risk of serious bacterial infections
    Bressler, Brian
    Korzenik, Joshua R.
    Canning, Claire
    Solomon, Daniel
    Schneeweiss, Sebastian
    [J]. GASTROENTEROLOGY, 2008, 134 (04) : A144 - A144
  • [5] Infliximab use in patients with inflammatory bowel disease and the risk of serious bacterial infections.
    Schneeweiss, S.
    Slomon, D. H.
    Korzenik, J.
    Canning, C.
    Bressler, B.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S43 - S43
  • [6] Low Ultraviolet Exposure Is Associated With Increased Risk of Hospitalization in Inflammatory Bowel Disease
    Limketkai, Berkeley
    Bayless, Theodore
    Brant, Steven
    Hutfless, Susan
    [J]. INFLAMMATORY BOWEL DISEASES, 2012, 18 : S34 - S35
  • [7] Antibodies Against Infliximab Are Associated With Increased Risk of Anti-Adalimumab Antibody Development in Patients With Inflammatory Bowel Disease
    Frederiksen, Madeline T.
    Ainsworth, Mark A.
    Brynskov, Jorn
    Thomsen, Ole
    Bendtzen, Klaus
    Steenholdt, Casper
    [J]. GASTROENTEROLOGY, 2014, 146 (05) : S238 - S238
  • [8] Antibodies against infliximab are associated with increased risk of anti-adalimumab antibody development in patients with inflammatory bowel disease
    Frederiksen, M. T.
    Ainsworth, M. A.
    Brynskov, J.
    Thomsen, O. O.
    Bendtzen, K.
    Steenholdt, C.
    [J]. JOURNAL OF CROHNS & COLITIS, 2014, 8 : S300 - S300
  • [9] Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections
    Schneeweiss, S.
    Korzenik, J.
    Solomon, D. H.
    Canning, C.
    Lee, J.
    Bressler, B.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 30 (03) : 253 - 264
  • [10] Obesity is associated with a higher risk of immunogenicity to adalimumab, but not to infliximab in patients with Inflammatory Bowel Disease
    Mahmoud, R.
    Schultheiss, J.
    Louwers, J.
    van der Kaaij, M.
    van Hellemondt, B.
    Mahmmod, N.
    van Boeckel, P.
    Jharap, B.
    Fidder, H.
    Oldenburg, B.
    [J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S420 - S421
12345